Eisai, Biogen get U.S. FDA approval for Alzheimer’s drug, apply for full approval

The U.S. Food and Drug Administration on Friday approved the Alzheimer’s drug lecanemab developed by Eisai Co Ltd and Biogen Inc for patients in the earliest stages of the mind-wasting disease. Eisai and Biogen said on Saturday the Japanese drugmaker had applied for full FDA approval of the drug.

About the Author

View All Posts